📰 Rom News
Page 351 - Rom News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rom. Real-time updates on events, politics, business and more.
June 5, 2023
Tighter lending standards from regional banks are making it harder for U.S. hotel developers to secure funding, slowing construction of new hotels at a time Americans appetite for travel is ripe.... | June 5, 2023
June 5, 2023
Of the 288 casualties in the Odisha train tragedy, seven are from Bihar, and 36 others had sustained grievous injuries while six have been reported missing.
June 5, 2023
Patrick Hummel from UBS retains his positive opinion on the stock with a Buy rating. The target price remains unchanged at EUR 36. | June 5, 2023
June 5, 2023
Deutsche Bank Research upgraded Tui from hold to buy and adjusted its price target of 9.80 euros to reflect the recent capital increase. The tourism group has seen a strong operating recovery in... | June 5, 2023
June 5, 2023
Already positive, the research from Deutsche Bank and its analyst James Hubbard still consider the stock as a Buy opportunity. The target price is unchanged and still at GBX 2907. | June 5, 2023
June 5, 2023
$46 million invested; IRR of over 30%TORONTO, June 05, 2023 -- Flow Capital Corp reports on its investment performance over the 5-year period from March 2018, when the formation of Flow was first... | June 5, 2023
June 5, 2023
Patrick Hummel from UBS retains his positive opinion on the stock with a Buy rating. The target price remains unchanged at USD 220. | June 5, 2023
June 5, 2023
MTN Group is pleased to announce the appointment of M. Mudassar Aqil as Executive: BankTech, in its Fintech business, MoMo, effective from 1 August 2023. BankTech, is one of MTN Fintechs five... | June 5, 2023
June 5, 2023
THOUSAND OAKS - Amgen today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated... | June 5, 2023
June 5, 2023
CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT and lazertinib, a... | June 5, 2023